EXIM PHARMA
ActiveFrom the official registers: KBO 4 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
The computed 12-month bankruptcy probability of EXIM PHARMA is 3.6% (moderate). The 2025 annual accounts show negative equity (-€546,144) and a net result of -€190,058. Equity has been shrinking by about 55% per year since 2022. Its solvency ranks better than 7% of 13,716 sector peers (NACE 46, financial year 2025). The company has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Deadline for the 2026 accounts:
2026
12-10
financial year 2025 · micro format · 73 days late
2025
31-12
Financial
Weakest financial yearnet -€190,058
The net result drops to -€190,058, the lowest from 2022 to 2025.
29-08
financial year 2024 · micro format · 29 days late
2024
31-12
Financial
Liquidity more than doubledcurrent ratio 1.22
The current ratio rises from 0.48 to 1.22.
03-07
Gazette deed
Resignation: Bright Views (director)Permanent representatives: Bouhjar llyes and Deprez Christian · Appointment: Christian Deprez Consulting (director)5 points ▸
Gazette deed
Resignation: Bright Views (director)
Permanent representatives: Bouhjar llyes and Deprez Christian · Appointment: Christian Deprez Consulting (director)5 points ▸
- General meeting, 23-01-2024
- Director resignation, Bright Views (director)
- Permanent representative, Bouhjar llyes
- Director appointment, Christian Deprez Consulting (director (not named in the articles))
- Permanent representative, Deprez Christian
10-06
financial year 2023 · micro format
2023
16-06
financial year 2022 · micro format
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank